Core Viewpoint - The company has shown significant growth in 2024, with plans for further development and investor returns, including a share buyback plan for 2025 [1][2][3] Group 1: Financial Performance - In 2024, the company achieved a revenue of 21.6096 billion yuan, a year-on-year increase of 42.95%, and a net profit attributable to shareholders of 5.869 billion yuan, up 117.01% [2] - In Q1 2025, the company reported a revenue of 5.440 billion yuan, a 20.91% increase year-on-year, and a net profit of 1.880 billion yuan, reflecting a 116.18% growth, marking a historical high for quarterly profit [2] Group 2: Business Development - The company is in the trial production phase of an 18,000-ton liquid methionine project in partnership with Sinopec [2] - The company has a current production capacity of 1,000 tons for the high-end coating HA project and has plans for new materials across three bases in Zhejiang, Shandong, and Tianjin [2] Group 3: Shareholder Returns - The company distributed a total cash dividend of 2.151 billion yuan in 2024, which includes a proposed cash dividend of 1.5367 billion yuan and a special dividend of 614.7 million yuan [2] - To boost market confidence, the company announced a share buyback plan for 2025, with an amount ranging from 300 million to 600 million yuan [1][2] Group 4: Future Outlook - The company aims to continue its ESG development strategy, focusing on integrated, series, and collaborative development in the "Chemical+" and "Biological+" sectors [3] - Plans include enhancing application research and service capabilities, driving innovation, and expanding the product and project pipeline while strengthening technological and industrial platforms [3]
新和成:一季度开门红 新产品、新项目储备丰富推进稳步增长